Skip to main content

Advertisement

Figure 2 | Cancer Cell International

Figure 2

From: Treatment with the PARP inhibitor, niraparib, sensitizes colorectal cancer cell lines to irinotecan regardless of MSI/MSS status

Figure 2

MSI cell lines do not respond better to niraparib monotherapy than MSS cell lines, but do respond better to SN-38 than MSS lines. A. MSI cell lines are not significantly more sensitive to niraparib than MSS cell lines. Niraparib EC50 values from 7 day proliferation assays in 12 MSI and 13 MSS CRC cancer cell lines. Each symbol indicates the EC50 of a single cell line and results are representative of 2 independent experiments. Cell lines that did not respond to niraparib within the tested dose range (10000 nM and below) are shown at 10000 nM. B. MSI cell lines are more sensitive to SN-38 treatment than MSS cell lines. Niraparib EC50 values from 7 day proliferation assays in 12 MSI and 13 MSS CRC cancer cell lines. Each symbol indicates the EC50 of a single cell line and results are representative of 2 independent experiments. Cell lines that did not respond to niraparib within the tested dose range (100 nM and below) are shown at 100 nM. The Wilcoxon rank sum test was performed to determine statistical significance.

Back to article page